Centivax Raises $45M in Funding to Launch First-Ever Universal Flu Vaccine to Human Trials - Tech Startups

Centivax raises $45M in funding to launch first-ever universal flu vaccine to human trials - Tech Startups

Centivax is betting big on ending the flu as we know it. The biotech startup just closed a $45 million Series A round to bring what it says could be the first universal flu vaccine into human trials. The raise […] The post Centivax raises $45M in funding to launch first-ever universal flu vaccine to human trials first appeared on Tech Startups.

Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio

Oversubscribed round was led by Future Ventures, and included NFX, BOLD Capital Partners, Kendall Capital Partners, Amplify Bio, Base4 Capital and othersDr. Emilio Emini, former SVP of Vaccine Research and Development at Pfizer, SVP of Research at Merck, and CEO…

Experimental flu drug may protect better than flu vaccines, company data show

The drug's prevention efficacy was 76% in the 450-mg group, 61% in the 300-mg group, and 58% in the 150-mg group.

Centivax Raises $45M to Commercialize First Universal Flu Vaccine

What You Should Know: –  Centivax, a biotech company developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. – The new funding will advance Centivax’s lead universal flu vaccine candidate through CMC development and into a Phase I trial within eight months. …